Nomogram to Predict Progression-free Survival in Patients with Well-differentiated, Stage IV Gastroenteropancreatic Neuroendocrine Tumors Treated with Somatostatin Analogues: Data of TRASGU-GETNE Study

被引：0
|
作者：
Jimenez-Fonseca, P. [1 ]
Alonso, V [2 ]
Riesco, M. C. [3 ]
Custodio, A. [4 ]
Molina-Cerrillo, J. [5 ]
Sanchez Canovas, M. [6 ]
Benavent, M. [7 ]
Hernando Cubero, J. [8 ]
La Casta, A. [9 ]
Lopez, C. [10 ]
Marazuela Azpiroz, M. [11 ]
Carmona-Bayonas, A. [12 ]
机构：
[1] Hosp Univ Cent Asturias, Dept Med Oncol, Oviedo, Spain
[2] Hosp Univ Miguel Servet, Dept Med Oncol, Zaragoza, Spain
[3] Hosp Univ Doce Octubre, Dept Med Oncol, Madrid, Spain
[4] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain
[5] Hosp Univ Ramon & Cajal, Dept Med Oncol, Madrid, Spain
[6] Hosp Univ Morales Meseguer, Dept Med Oncol, Murcia, Spain
[7] Hosp Univ Virgen Rocio, Dept Med Oncol, Seville, Spain
[8] Hosp Univ Vall dHebron, Dept Med Oncol, Barcelona, Spain
[9] Hosp Univ Donostia, Dept Med Oncol, San Sebastian, Spain
[10] Hosp Univ Marques Valdecilla, Dept Med Oncol, Santander, Spain
[11] Complejo Hosp La Princesa, Dept Endocrinol, Madrid, Spain
[12] Univ Murcia, Hosp Univ Morales Meseguer Murcia, Dept Med Oncol, UMU,IMIB, Murcia, Spain
来源：
NEUROENDOCRINOLOGY | 2019年 / 108卷
关键词：
cox regression; prognosis; registry; tool;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
D28
引用
收藏
页码：67 / 67
页数：1
相关论文
共 31 条
  • [11] The impact of metformin on progression-free survival in patients with advanced pancreatic well differentiated neuroendocrine tumor receiving everolimus plus somatostatin analogue treatment
    Pusceddu, Sara
    Buzzoni, Roberto
    Concas, Laura
    Bregant, Cristina
    Leuzzi, Livia
    Milione, Massimo
    Seregni, Ettore
    Formisano, Barbara
    Consonni, Paola
    De Braud, Filippo
    CANCER RESEARCH, 2015, 75
  • [12] METFORMIN IMPACT ON PROGRESSION-FREE SURVIVAL IN ADVANCED PANCREATIC WELL-DIFFERENTIATED NEUROENDOCRINE TUMORS (PWDNETS). RETROSPECTIVE EVALUATION IN DIABETIC PATIENTS RECEIVING EVEROLIMUS PLUS OCTREOTIDE LAR TREATMENT
    Pusceddu, S.
    De Braud, F. G. M.
    Concas, L.
    Bregant, C.
    Festinese, F.
    Giacomelli, L.
    D'Autilia, E.
    Formisano, B.
    Mazzaferro, V.
    Buzzoni, R.
    ANNALS OF ONCOLOGY, 2014, 25
  • [13] Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response
    Lamarca, Angela
    Barriuso, Jorge
    Kulke, Matthew
    Borbath, Ivan
    Lenz, Heinz-Josef
    Raoul, Jean Luc
    Meropol, Neal J.
    Lombard-Bohas, Catherine
    Posey, James
    Faivre, Sandrine
    Raymond, Eric
    Valle, Juan W.
    BRITISH JOURNAL OF CANCER, 2018, 118 (02) : 181 - 188
  • [14] Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response
    Angela Lamarca
    Jorge Barriuso
    Matthew Kulke
    Ivan Borbath
    Heinz-Josef Lenz
    Jean Luc Raoul
    Neal J Meropol
    Catherine Lombard-Bohas
    James Posey
    Sandrine Faivre
    Eric Raymond
    Juan W Valle
    British Journal of Cancer, 2018, 118 : 181 - 188
  • [15] Lanreotide Autogel Significantly Improves Tumor Progression-Free Survival in Patients with Non-Functioning Gastroenteropancreatic Neuroendocrine Tumors: Results of the CLARINET Study
    Caplin, Martyn
    Phan, Alexandria
    Liyanage, Nilani
    Gomez-Panzani, Edda
    Blumberg, Joelle
    PANCREAS, 2014, 43 (03) : 495 - 495
  • [16] EVALUATION OF PROGRESSION-FREE SURVIVAL (PFS) BY BLINDED INDEPENDENT CENTRAL REVIEW (BICR) IN PATIENTS (PTS) WITH PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMOURS (NET) TREATED WITH SUNITINIB (SU) OR PLACEBO
    van Cutsem, E.
    Dahan, L.
    Patyna, S.
    Klademenos, D.
    Lu, D. R.
    Chao, R.
    Faivre, S.
    Raymond, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 235 - 235
  • [17] Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib A Phase 2 Clinical Trial
    Dickson, Mark A.
    Schwartz, Gary K.
    Keohan, Mary Louise
    D'Angelo, Sandra P.
    Gounder, Mrinal M.
    Chi, Ping
    Antonescu, Cristina R.
    Landa, Jonathan
    Qin, Li-Xuan
    Crago, Aimee M.
    Singer, Samuel
    Koff, Andrew
    Tap, William D.
    JAMA ONCOLOGY, 2016, 2 (07) : 937 - 940
  • [18] Determination of an Optimal Response Cut-Off to Predict Progression-Free Survival(PFS) in Patients(pts) with Well-Differentiated Advanced Pancreatic Neuroendocrine Tumours(pNETs) Treated with Sunitinib(S): An Alternative to the Current RECIST-Response
    Lamarca, A.
    Barriuso, J.
    Kulke, M. H.
    Borbath, I
    Lenz, H. J.
    Raoul, J. L.
    Meropol, N. J.
    Lombard-Bohas, C.
    Posey, J.
    Faivre, S.
    Raymond, E.
    Valle, J. W.
    NEUROENDOCRINOLOGY, 2017, 105 : 216 - 216
  • [19] Gamma-Glutamyl Transferase (GGT) as an Early Predictor of Better Progression-Free Survival in Well-Differentiated Gastroenteropancreatic Neuro-Endocrine Tumors (GEP-NET) in Different Lines of Treatment
    Armentano, D. P.
    Monteiro, M.
    Aguiar, P.
    Brandao, R.
    Tsukamoto, J.
    Pio, R.
    Arakelian, R.
    Araujo, R.
    Uson, P.
    NEUROENDOCRINOLOGY, 2019, 108 : 177 - 177
  • [20] Biodistribution and Dosimetry Evaluation of the Radiolabeled Somatostatin Receptor Antagonist 68Ga-DATA5m LM4 in Molecular Imaging of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors Patients
    Ballal, Sanjana
    Sheokand, Parvind
    Yadav, Madhav P.
    Roesch, Frank
    Viswanathan, Rahul
    Satapathy, Swayamjeet
    Tripathi, Madhavi
    Moon, Euy Sung
    Mishra, Prashant
    Rastogi, Sameer
    Agarwal, Shipra
    Bal, Chandrasekhar
    CLINICAL NUCLEAR MEDICINE, 2025, 50 (04) : e194 - e201
1234